XML 70 R52.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Summary of Segment Profit |
a. | Segment information:
|  | Year ended December 31, |
|  | 2024 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 8,034 |  |  | $ | 5,103 |  |  | $ | 2,463 |
Cost of sales |  |  | 3,646 |  |  |  | 2,197 |  |  |  | 1,229 |
R&D expenses |  |  | 633 |  |  |  | 229 |  |  |  | 112 |
S&M expenses |  |  | 1,049 |  |  |  | 826 |  |  |  | 534 |
G&A expenses |  |  | 410 |  |  |  | 272 |  |  |  | 150 |
Other loss (income) |  |  | § |  |  |  | 3 |  |  |  | (2 | )
Segment profit |  | $ | 2,296 |  |  | $ | 1,575 |  |  | $ | 440 |
§ | Represents an amount less than $0.5 million.
|  | Year ended December 31, |
|  | 2023 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 7,731 |  |  | $ | 4,837 |  |  | $ | 2,351 |
Cost of sales |  |  | 3,421 |  |  |  | 2,111 |  |  |  | 1,191 |
R&D expenses |  |  | 604 |  |  |  | 220 |  |  |  | 104 |
S&M expenses |  |  | 938 |  |  |  | 767 |  |  |  | 487 |
G&A expenses |  |  | 378 |  |  |  | 263 |  |  |  | 142 |
Other loss (income) |  |  | (5 | ) |  |  | (2 | ) |  |  | (39 | )
Segment profit |  | $ | 2,394 |  |  | $ | 1,478 |  |  | $ | 465 |
|  | Year ended December 31, |
|  | 2022 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 7,003 |  |  | $ | 4,525 |  |  | $ | 2,352 |
Cost of sales |  |  | 3,269 |  |  |  | 1,825 |  |  |  | 1,128 |
R&D expenses |  |  | 485 |  |  |  | 213 |  |  |  | 119 |
S&M expenses |  |  | 879 |  |  |  | 748 |  |  |  | 467 |
G&A expenses |  |  | 440 |  |  |  | 246 |  |  |  | 154 |
Other loss (income) |  |  | (3 | ) |  |  | (3 | ) |  |  | (54 | )
Segment profit |  | $ | 1,934 |  |  | $ | 1,496 |  |  | $ | 538 |
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
United States profit |  | $ | 2,296 |  |  | $ | 2,394 |  |  | $ | 1,934 |
Europe profit |  |  | 1,575 |  |  |  | 1,478 |  |  |  | 1,496 |
International Markets profit |  |  | 440 |  |  |  | 465 |  |  |  | 538 |
Total reportable segments profit |  |  | 4,311 |  |  |  | 4,338 |  |  |  | 3,968 |
Profit of other activities |  |  | 18 |  |  |  | 24 |  |  |  | 172 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |  |  |  | — |
Amortization |  |  | 588 |  |  |  | 616 |  |  |  | 732 |
Other assets impairments, restructuring and other items |  |  | 1,388 |  |  |  | 718 |  |  |  | 512 |
Goodwill impairment |  |  | 1,280 |  |  |  | 700 |  |  |  | 2,045 |
Intangible assets impairments |  |  | 251 |  |  |  | 350 |  |  |  | 355 |
Legal settlements and loss contingencies |  |  | 761 |  |  |  | 1,043 |  |  |  | 2,082 |
Other unallocated amounts |  |  | 364 |  |  |  | 502 |  |  |  | 610 |
Consolidated operating income (loss) |  |  | (303 | ) |  |  | 433 |  |  |  | (2,197 | )
Financial expenses, net |  |  | 981 |  |  |  | 1,057 |  |  |  | 966 |
Consolidated income (loss) before income taxes |  | $ | (1,284 | ) |  | $ | (624 | ) |  | $ | (3,163 | )
Schedule of Net Sales by Product Line | The following tables present revenues by major products and activities for each segment for the year ended December 31, 2024, 2023 and 2022: United States segment:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
Generic products (including biosimilars) |  | $ | 3,599 |  |  | $ | 3,138 |  |  | $ | 3,155 |
AJOVY |  |  | 207 |  |  |  | 211 |  |  |  | 210 |
AUSTEDO |  |  | 1,642 |  |  |  | 1,225 |  |  |  | 963 |
BENDEKA and TREANDA |  |  | 168 |  |  |  | 237 |  |  |  | 309 |
COPAXONE |  |  | 242 |  |  |  | 297 |  |  |  | 359 |
UZEDY |  |  | 117 |  |  |  | 23 |  |  |  | — |
Anda |  |  | 1,536 |  |  |  | 1,577 |  |  |  | 1,471 |
Other* |  |  | 523 |  |  |  | 1,025 |  |  |  | 536 |
Total |  | $ | 8,034 |  |  | $ | 7,731 |  |  | $ | 7,003 |
* | Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s duvakitug (anti-TL1A) asset (see note 2).
Europe segment:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 3,926 |  |  | $ | 3,664 |  |  | $ | 3,466 |
AJOVY |  |  | 216 |  |  |  | 160 |  |  |  | 124 |
COPAXONE |  |  | 213 |  |  |  | 231 |  |  |  | 268 |
Respiratory products |  |  | 244 |  |  |  | 265 |  |  |  | 273 |
Other* |  |  | 504 |  |  |  | 516 |  |  |  | 393 |
Total |  | $ | 5,103 |  |  | $ | 4,837 |  |  | $ | 4,525 |
* | Other revenues in 2024 and 2023 include the sale of certain product rights.
International Markets segment:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 1,937 |  |  | $ | 1,932 |  |  | $ | 1,980 |
AJOVY |  |  | 84 |  |  |  | 63 |  |  |  | 42 |
COPAXONE |  |  | 48 |  |  |  | 63 |  |  |  | 64 |
AUSTEDO |  |  | 46 |  |  |  | 15 |  |  |  | 8 |
Other* |  |  | 349 |  |  |  | 278 |  |  |  | 257 |
Total |  | $ | 2,463 |  |  | $ | 2,351 |  |  | $ | 2,352 |
Schedule of Sales Percentage by Therapeutic Category | The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2024, 2023 and 2022.
|  | Percentage of Third Party Net Sales |
|  | 2024 |  |  | 2023 |  |  | 2022 |
McKesson Corporation |  |  | 12 | % |  |  | 9 | % |  |  | 10 | %
AmerisourceBergen Corporation |  |  | 9 | % |  |  | 9 | % |  |  | 10 | %
Schedule of Property, Plant and Equipment by Geographic Location |
|  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (U.S. $ in millions) |
Israel |  | $ | 1,066 |  |  | $ | 1,312 |
Germany |  |  | 1,262 |  |  |  | 1,318 |
United States |  |  | 561 |  |  |  | 596 |
Croatia |  |  | 277 |  |  |  | 447 |
Czech republic |  |  | 206 |  |  |  | 309 |
Hungary |  |  | 83 |  |  |  | 279 |
Ireland |  |  | 261 |  |  |  | 266 |
Other |  |  | 865 |  |  |  | 1,222 |
Total property, plant and equipment |  | $ | 4,581 |  |  | $ | 5,750 |

X
- Definition A schedule indicating where long-lived tangible assets are located. + References No definition available. + Details
Name: | teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition A schedule of net sales by therapeutic category, stated as a percentage of total sales. + References No definition available. + Details
Name: | teva_SalesPercentageByTherapeuticCategoryTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration